117 related articles for article (PubMed ID: 10082242)
1. CCK4-induced panic in healthy subjects II: neurochemical correlates.
Jerabek I; Boulenger JP; Bradwejn J; Drumheller A; Lavallée YJ; Jolicoeur FB
Eur Neuropsychopharmacol; 1999 Jan; 9(1-2):157-64. PubMed ID: 10082242
[TBL] [Abstract][Full Text] [Related]
2. CCK4-induced panic in healthy subjects I: psychological and cardiovascular effects.
Jerabek I; Boulenger JP; Bradwejn J; Lavallée YJ; Jolicoeur FB
Eur Neuropsychopharmacol; 1999 Jan; 9(1-2):149-55. PubMed ID: 10082241
[TBL] [Abstract][Full Text] [Related]
3. The panic-inducing properties of the cholecystokinin tetrapeptide CCK4 in patients with panic disorder.
van Megen HJ; Westenberg HG; Den Boer JA; Kahn RS
Eur Neuropsychopharmacol; 1996 Aug; 6(3):187-94. PubMed ID: 8880078
[TBL] [Abstract][Full Text] [Related]
4. Functional neuroanatomy of CCK4-induced anxiety in normal healthy volunteers.
Benkelfat C; Bradwejn J; Meyer E; Ellenbogen M; Milot S; Gjedde A; Evans A
Am J Psychiatry; 1995 Aug; 152(8):1180-4. PubMed ID: 7625467
[TBL] [Abstract][Full Text] [Related]
5. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks.
van Megen HJ; Westenberg HG; den Boer JA; Slaap B; Scheepmakers A
Psychopharmacology (Berl); 1997 Feb; 129(4):357-64. PubMed ID: 9085405
[TBL] [Abstract][Full Text] [Related]
6. The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients.
van Megen HJ; Westenberg HG; den Boer JA; Slaap B; van Es-Radhakishun F; Pande AC
Psychopharmacology (Berl); 1997 Feb; 129(3):243-8. PubMed ID: 9084062
[TBL] [Abstract][Full Text] [Related]
7. Effects of tyrosine and tryptophan ingestion on plasma catecholamine and 3,4-dihydroxyphenylacetic acid concentrations.
Rasmussen DD; Ishizuka B; Quigley ME; Yen SS
J Clin Endocrinol Metab; 1983 Oct; 57(4):760-3. PubMed ID: 6885965
[TBL] [Abstract][Full Text] [Related]
8. Distribution of free and conjugated catecholamines between plasma, platelets and erythrocytes: different effects of intravenous and oral catecholamine administrations.
Ratge D; Kohse KP; Steegmüller U; Wisser H
J Pharmacol Exp Ther; 1991 Apr; 257(1):232-8. PubMed ID: 2019988
[TBL] [Abstract][Full Text] [Related]
9. Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients.
van Megen HJ; Westenberg HG; den Boer JA; Haigh JR; Traub M
Psychopharmacology (Berl); 1994 Apr; 114(3):449-55. PubMed ID: 7855203
[TBL] [Abstract][Full Text] [Related]
10. Sodium depletion increases platelet and plasma catecholamines in hypertensive men.
Kjeldsen SE; Westheim A; Lande K; Gjesdal K; Leren P; Enger E; Eide IK
Hypertension; 1988 May; 11(5):477-82. PubMed ID: 3366481
[TBL] [Abstract][Full Text] [Related]
11. Distribution of free and sulfate-conjugated catecholamines in human platelets.
McCulloch RK; Vandongen R; Tunney AM; Beilin LJ; Rogers PB
Am J Physiol; 1987 Sep; 253(3 Pt 1):E312-6. PubMed ID: 3631259
[TBL] [Abstract][Full Text] [Related]
12. Effects of handling or immobilization on plasma levels of 3,4-dihydroxyphenylalanine, catecholamines, and metabolites in rats.
Kvetnanský R; Goldstein DS; Weise VK; Holmes C; Szemeredi K; Bagdy G; Kopin IJ
J Neurochem; 1992 Jun; 58(6):2296-302. PubMed ID: 1573408
[TBL] [Abstract][Full Text] [Related]
13. Effect of eprosartan on catecholamines and peripheral haemodynamics in subjects with insulin-induced hypoglycaemia.
Christensen M; Ibsen H; Worck R
Clin Sci (Lond); 2005 Feb; 108(2):113-9. PubMed ID: 15383007
[TBL] [Abstract][Full Text] [Related]
14. Psychotic and nonpsychotic depressions: II. Platelet MAO activity, plasma catecholamines, cortisol, and specific symptoms.
Schatzberg AF; Rothschild AJ; Langlais PJ; Lerbinger JE; Schildkraut JJ; Cole JO
Psychiatry Res; 1987 Feb; 20(2):155-64. PubMed ID: 3575560
[TBL] [Abstract][Full Text] [Related]
15. Platelet catecholamines in migraine.
D'Andrea G; Welch KM; Nagel-Leiby S; Grunfeld S; Joseph R
Cephalalgia; 1989 Mar; 9(1):3-5. PubMed ID: 2706673
[TBL] [Abstract][Full Text] [Related]
16. Plasma catecholamine levels before and after paroxetine treatment in patients with panic disorder.
Oh JY; Yu BH; Heo JY; Yoo I; Song H; Jeon HJ
Psychiatry Res; 2015 Feb; 225(3):471-5. PubMed ID: 25529258
[TBL] [Abstract][Full Text] [Related]
17. Platelet alpha 2-adrenergic receptor binding and plasma catecholamines. Before and during imipramine treatment in patients with panic anxiety.
Cameron OG; Smith CB; Hollingsworth PJ; Nesse RM; Curtis GC
Arch Gen Psychiatry; 1984 Dec; 41(12):1144-8. PubMed ID: 6095785
[TBL] [Abstract][Full Text] [Related]
18. The effect of 6-week treatment with escitalopram on CCK-4 challenge: a placebo-controlled study in CCK-4-sensitive healthy volunteers.
Tõru I; Maron E; Raag M; Vasar V; Nutt DJ; Shlik J
Eur Neuropsychopharmacol; 2013 Jul; 23(7):645-52. PubMed ID: 22939006
[TBL] [Abstract][Full Text] [Related]
19. [Determination of plasma catecholamine. Effects of glucagon administration].
Conte-Devolx B; Oliver C; Orlando M; Aquaron R; Giraud P; Gillioz P; Amabile G; Henry JF; Daheme D; Codaccioni JL; Serradimigni A
Arch Mal Coeur Vaiss; 1982 Jun; 75 Spec No():85-9. PubMed ID: 6810834
[TBL] [Abstract][Full Text] [Related]
20. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder.
Bradwejn J; Koszycki D; Couëtoux du Tertre A; van Megen H; den Boer J; Westenberg H
Arch Gen Psychiatry; 1994 Jun; 51(6):486-93. PubMed ID: 8192551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
